Table 2

Baseline patient characteristics
RTOG-85-31[9,10] Granfors et al.[11,12] EST-3886[13-15] EPC program[16,17]
early AST (n = 98) deferred AST (n = 75) early AST (n = 19) deferred AST (n = 20) early AST (n = 47) deferred AST (n = 51) early/deferred AST (n = 150) (a)
Age (years) median 64 median 66 mean 68.8 median 65.1 median 66.6 mean 64.6
(range 44–79) (range 50–77) (range 49.2-75.3) (range 52–75) (range 45–78) (range 52–84)
Gleason score (n) not known 10 10 - - 3 6 5
2-4 - - - - - - 22
5-6 - - - - - - 60
3-6 - - - - 9 11 -
2-7 55 43 - - - - -
7 - - - - 26 29 -
7-10 - - - - - - 63
8-10 33 22 - - 9 5 -
Grade (n) G1 - - 3 4 - - -
G2 - - 13 12 - - -
G3 - - 4 3 - - -
T stage (n) T1 3 6 2 2 - - 43
T2 68 53 13 11 - - 98
T3 27 16 4 6 - - 9
T4 - - 1 0 - - 0
Positive surgical margins (n) - - - - 32 31 -
Positive seminal vesicle (n) - - - - 27 32 -
Nodal status (n) assessed - - - - median 11 median 14 -
(range 3–36) (range 2–39)
positive - - - - median 2 median 2 -
(range 1–19) (range 1–20)

(a). Authors reported data for baseline patient characteristics only for the group of patients with node-positive prostate cancer but not for patients randomized to early or deferred androgen suppression therapy.

Kunath et al.

Kunath et al. BMC Cancer 2013 13:131   doi:10.1186/1471-2407-13-131

Open Data